dc.contributor.author | Cil, I | |
dc.contributor.author | EKENEL, Meltem | |
dc.contributor.author | Zirtiloglu, A. | |
dc.contributor.author | Karabulut, S. | |
dc.contributor.author | Tural, D. | |
dc.contributor.author | Aydin, E. | |
dc.date.accessioned | 2021-03-06T10:52:13Z | |
dc.date.available | 2021-03-06T10:52:13Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | EKENEL M., Karabulut S., Cil I., Zirtiloglu A., Aydin E., Tural D., "Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience", ACTAS UROLOGICAS ESPANOLAS, cilt.44, ss.27-33, 2020 | |
dc.identifier.issn | 0210-4806 | |
dc.identifier.other | av_ec6724dd-c483-40d3-a655-8243ee684eb9 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/155211 | |
dc.identifier.uri | https://doi.org/10.1016/j.acuro.2019.06.007 | |
dc.description.abstract | Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice. | |
dc.language.iso | eng | |
dc.subject | Nefroloji | |
dc.subject | ÜROLOJİ VE NEFROLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.title | Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience | |
dc.type | Makale | |
dc.relation.journal | ACTAS UROLOGICAS ESPANOLAS | |
dc.contributor.department | İstanbul Üniversitesi , Onkoloji Enstitüsü , Teşhis Tedavi Ve Bakım Hizmetleri | |
dc.identifier.volume | 44 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 27 | |
dc.identifier.endpage | 33 | |
dc.contributor.firstauthorID | 2211239 | |